Key result
Perioperative heparin bridging in surgical mechanical heart valve patients showed no clear benefit for thromboembolism and increased the risk of major bleeding.
Why the study?
Perioperative heparin bridging in surgical MHV patients aims to prevent thromboembolism but risks bleeding, and comparative data on net clinical outcomes versus no bridging were lacking.
Does perioperative heparin bridging reduce thromboembolism or improve net clinical outcomes in surgical mechanical heart valve patients?
Meta-Analysis (n=1,847)
Does perioperative heparin bridging reduce thromboembolism or improve net clinical outcomes in surgical mechanical heart valve patients?
Routine perioperative heparin bridging in surgical mechanical heart valve patients increases bleeding risk without providing meaningful thromboembolic benefit, supporting a shift toward selective, risk-adapted management.
Answers are grounded in this paper and cite their sources.
Increases major bleeding without thromboembolic benefit; challenges routine bridging and leaves selective strategies open for trials.
Abstract Introduction Perioperative heparin bridging in surgical mechanical heart valve (MHV) patients aims to prevent thromboembolism but risks bleeding. Addressing a lack of comparative data, this study synthesizes current literature to evaluate the net clinical outcomes of bridging versus no bridging. Purpose To perform a meta-analysis providing clinically actionable estimates of the benefits and risks of perioperative bridging in surgical MHV patients. Methods We systematically searched PubMed, Embase, and the Cochrane Library for studies comparing heparin bridging versus no bridging in surgical MHV patients. We used a Bayesian random-effects meta-analysis to estimate risk ratios (RRs) and 95% credible intervals (95% CrIs). Posterior probabilities were then calculated to assess the treatment benefit or harm. Results Four studies comprising 1847 patients (64.48% bridged) met the inclusion criteria. The estimated RR for thromboembolism was 1.36 (95% CrI, 0.27 to 6.97), with only a 35.1% posterior probability of risk reduction (RR ≤ 1), suggesting no clear benefit. All-cause mortality estimates were uncertain (RR, 0.68; 95% CrI, 0.12 to 3.90). Conversely, safety endpoints yielded high probabilities of hemorrhagic complications. The RR for major bleeding was 2.04 (95% CrI, 0.81 to 5.14), carrying an 82.5% probability of clinically meaningful harm (RR > 1.33). Minor bleeding showed a similar pattern (RR, 1.53; 95% CrI, 0.61 to 3.93). Conclusions Routine perioperative heparin bridging in surgical MHV patients increases bleeding risk without meaningful thromboembolic benefit, supporting a shift toward selective, risk-adapted management. Registration PROSPERO identifier no. CRD420261359162.
No takes yet. Share an insight, caveat, or question.
Batista et al. (2026) conducted a meta-analysis in Surgical mechanical heart valve (MHV) (n=1,847). Perioperative heparin bridging vs. No bridging was evaluated on Thromboembolism (RR 1.36, 95% CI 0.27 to 6.97). Perioperative heparin bridging in surgical mechanical heart valve patients showed no clear benefit for thromboembolism and increased the risk of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: